Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citationBardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Self-citationStarodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Self-citationCharacterization of human colon cancer antigens recognized by autologous antibodies
Scanlan, M. J., Chen, Y., Williamson, B., Gure, A. O., Stockert, E., Gordan, J. D., Türeci, Ö., Şahin, U., Pfreundschuh, M. G., & Old, L. J. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<628::aid-ijc3>3.0.co;2-s · Cited by 335
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Upregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Self-citationCardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Self-citationBeaver, J. A., Howie, L. J., Pelosof, L., Kim, T., Liu, J., Goldberg, K. B., Sridhara, R., Blumenthal, G. M., Farrell, A. T., Keegan, P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5618 · Cited by 298
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Self-citation3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · The Breast · doi:10.1016/j.breast.2016.10.001 · Cited by 228
Self-citationPlasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016) · Medicine · doi:10.1097/md.0000000000004614 · Cited by 201
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Zeichner, S. B., Terawaki, H., & Gogineni, K. (2016) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s32783 · Cited by 196
Sharkey, R. M., McBride, W. J., Cardillo, T. M., Govindan, S. V., Wang, Y., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0670 · Cited by 172
Self-citationKhosravi‐Shahi, P., Cabezón‐Gutiérrez, L., & Custodio‐Cabello, S. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12748 · Cited by 144
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 137
Self-citationThe Management of Early-Stage and Metastatic Triple-Negative Breast Cancer
Anders, C. K., Zagar, T. M., & Carey, L. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.003 · Cited by 109
Clinical and pharmacogenetic factors associated with irinotecan toxicity
Kweekel, D. M., Guchelaar, H., & Gelderblom, H. A. J. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.05.002 · Cited by 100
Chuk, M. K., Chang, J. T., Theoret, M. R., Sampene, E., He, K., Weis, S. L., Helms, W. S., Jin, R., Li, H., Yu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0663 · Cited by 92
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Perez, E. A., Patel, T., & Moreno‐Aspitia, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0824-0 · Cited by 90
Huang, H., Groth, J., Sossey‐Alaoui, K., Hawthorn, L., Beall, S. A., & Geradts, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2107 · Cited by 89
Falvella, F. S., Cheli, S., Martinetti, A., Mazzali, C., Iacovelli, R., Maggi, C., Gariboldi, M., Pierotti, M. A., Bartolomeo, M. D., Sottotetti, E., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12631 · Cited by 66
Twelves, C., Awada, A. H., Cortés, J., Yelle, L., Velikova, G., Olivo, M. S., Song, J., Dutcus, C. E., & Kaufman, P. A. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s39615 · Cited by 53
Park, I. H., Im, S., Jung, K. H., Sohn, J., Park, Y. H., Lee, K. S., Sim, S. H., Park, K. H., Kim, J. H., Nam, B., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.562 · Cited by 50
Liu, D., Li, J., Gao, J., Li, Y., Yang, R. R., & Shen, L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3406-2 · Cited by 27
Irinotecan Therapy and UGT1A1 Genotype
Dean, L. (2015) · Europe PMC (PubMed Central) · Cited by 26
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity
Riera, P., Salazar, J., Manrique, A. C. V., Tobeña, M., Sebio, A., Gallano, P., Barnadas, A., & Páez, D. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13574 · Cited by 26
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
“of patients (%) 54 (23) 89 (38) 65 (24) 100 (38)”
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Sacituzumab govitecan-hziy has demonstrated promising activity in advanced lines for triple-negative ABC in a phase I/II study of 108 patients who had received a range of 2-10 prior treatments for metastatic disease.(72) The overall response rate was 33.”
BackgroundSelf-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.